ReNeuron Appoints Principal Investigator For Phase l Clinical Study With Its ReN001 Stem Cell Therapy For Stroke
ReNeuron Group plc (LSE: RENE) today announces that it has appointed Professor Douglas Kondziolka MD, MSc, FRCS, FACS as Principal Investigator for the Phase l clinical study with its ReN001 stem cell therapy for disabled stroke patients. This appointment represents a further step in ReNeuron's preparations for the clinical phase of its development programme for ReN001. The Company intends to file an Investigational New Drug (IND) application for ReN001 with the US Food and Drug Administration (FDA) before the end of 2006. Approval of this application will open the way to commencement of a Phase I clinical study in the US, placing ReN001 at the forefront of clinical-stage neural stem cell treatments for major neurological conditions.